South China University of Technology and affiliated organizations have published data from a study that aimed to assess the role of the recently identified human hexokinase, hexokinase domain component 1 (HKDC1), in regulating tumor immune cell response in hepatocellular carcinoma (HCC).
Proto-oncogene Vav (VAV1) is a guanine exchange factor that is crucial for T- and B-cell receptor signaling. Assays in Vav1-knockout murine models had previously demonstrated diminished effector functions and resistance to autoimmune disease. Monte Rosa Therapeutics AG has presented data on the VAV1 inhibitor MRT-6160, a first-in-class molecule that targets VAV1 for proteasomal degradation, thought to potentially treat autoimmune diseases through the degradation of VAV1.
Alanine-serine-cysteine transporter 2 (ASCT2) is a glutamine (Gln) transporter that is required for cell proliferation and is overexpressed in tumors such as non-small-cell lung cancer (NSCLC). Researchers from China Pharmaceutical University have reported on the discovery and preclinical characterization of a novel series of ASCT2 inhibitors that led to the identification two lead compounds.
Since its founding by the National Institutes of Health (NIH), the scientists of the All of Us Research Program have set the goal to analyze the largest diversity of the genomic population in the country and end the under-representation of its different groups. The project has expanded the vision of several pathologies, discovered thousands of new genetic variants, redefined the risk genes for common diseases, and stratified them, uncovering eight different forms in the case of type 2 diabetes (T2D). Their results create a pathway for a new age of precision medicine.
Work at Beijing Earthwise Technology Co. Ltd. has led to the discovery of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors potentially useful for the treatment of cancer.
An Allorion Therapeutics (Guangzhou) Co. Ltd. patent discloses aminoheteroaryl CDK4/cyclin D1 inhibitors reported to be useful for the treatment of cancer.
Celgene Corp. has identified substituted imidazopyrazine compounds characterized as interleukin-1 receptor-associated kinase 3 (IRAK-3; IRAK-M) ligands and thus reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders.
Quinoxaline derivatives acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) and/or (E545K mutant) inhibitors have been described in a Black Diamond Therapeutics Inc. patent.
Shanghai Apeiron Biotechnology Co. Ltd. has patented new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
RSS
